1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?

 
• By Anju Ghangurde

Sun Pharma’s executive vice president, biologics and dermatology, Jesper Ostergaard Jensen, elaborates on some aspects of the recent encouraging data around the company’s late stage psoriasis asset, tildrakizumab. Jensen also tells Scrip that the firm is upbeat about its acne and photodynamic therapy products in the US.

Marathon runners
Sun Pharma's tildrakizumab faces a crowded competitive space • Source: Shutterstock

Sun Pharmaceutical Industries Ltd. has underscored the potential long-term efficacy of its late stage psoriasis asset, tildrakizumab, as part of recent new analyses from the Phase I and the pivotal Phase III clinical trials (reSURFACE 1 and 2) of the investigational IL-23p19 inhibitor.

The pivotal Phase III reSURFACE trial results presented to date are through week 64 and indicate “significantly improved” skin clearance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 
• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

 
• By Sushmita Panda

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

More from R&D

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 
• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

 
• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.